The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
CBT-I 对酗酒者的功效
基本信息
- 批准号:8634474
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-01 至 2018-12-31
- 项目状态:已结题
- 来源:
- 关键词:AbateAbstinenceAccountingAddressAftercareAge of OnsetAlcohol dependenceAlcoholismAlcoholsAnxietyBackBeck depression inventoryBiological MarkersClinicalCognitive TherapyCohort StudiesDataDisease remissionElectroencephalographyEquipment and supply inventoriesEvaluationExhibitsFamilyFamily history ofFatigueGeneral PopulationGeneralized Anxiety DisorderGeneticGoalsHealthHeavy DrinkingHourHygieneIncidenceIndividualInterventionInvestigationLaboratoriesLeadMaintenanceMeasuresMilitary PersonnelModalityMoodsOutcomeOutcome MeasureParticipantPatientsPerformance at workPharmaceutical PreparationsPharmacotherapyPhenotypePlacebosPopulationPrevalencePrimary Health CareProtocols documentationQuestionnairesRandomizedRecording of previous eventsRecoveryRecurrenceRegimenRelapseRelative (related person)Replacement TherapyResearchRiskRisk FactorsSamplingSeveritiesSeverity of illnessSleepSleeplessnessStimulusTestingTimeTimeLineTrainingTrazodoneTreatment outcomeVeteransWithdrawalalcohol cravingalcohol misusealcoholism therapyawakebasebinge drinkingclinical effectclinically significantcravingdaily functioningdepressive symptomsdesensitizationdesigndiariesdrinkingeffective therapyexperiencefallsfollow-upgabapentinhealth related quality of lifeimprovedindexingmalemodifiable riskpost interventionprimary outcomeproblem drinkerpublic health relevancerecidivismsleep regulationsobrietytraittreatment adherencetreatment effecttreatment responsetrend
项目摘要
Alcoholism and insomnia are highly prevalent in Veterans. Alcoholism is estimated to occur in about 6.4% of
Veterans. More recent estimates of alcohol misuse range from 11.8% in OIF Veterans to 21.8% in OEF/OIF
male Veterans. Insomnia is estimated to occur in about 28% of active duty military personnel (from the
Millennium Cohort Study), and up to 77% of Veterans seen in a VHA primary care experience clinically
significant levels of insomnia. Insomnia is also highly prevalent in patients recovering from alcoholism with as
many as 70% of such patients complaining of sleep initiation and/or maintenance problems. These prevalence
rates are 2-7 times higher than that of the general population. The direct consequences of insomnia include
sleepiness, fatigue, irritability, diminished work performance and impaired interpersonal functioning. The long-
term sequelae of insomnia include risk for new-onset and recurrent psychiatric illness, and in the context of
alcoholism, greater intensity of alcoholism and increased risk for relapse in abstinent alcoholics. At present,
there are nine studies which evaluate whether insomnia represents a modifiable risk factor for relapse of
alcoholism (2 investigating trazodone, 3 investigating gabapentin, 1 investigating ramelteon, and 3
investigating a modified form of cognitive-behavioral therapy for insomnia [CBT-I]). The results from these
studies are variable. The CBT-I investigations show the most promise in terms of improved sleep, but there is
no clear evidence that improved sleep has protective value against pathological drinking. Accordingly, CBT-I
(n=30) will be evaluated and compared to the Quasi-Desensitization Therapy (QDT) (n=30) in a sample of
veterans who have been sober for at least one month (but less than one year). The study cohort will be further
stratified into those who do (n=30) and do not (n=30) have a first-degree family history of alcoholism. Familial
alcoholism is taken into account, as this may represent a unique factor that contributes to insomnia severity
and/or treatment outcome. All subjects will complete a 2-week baseline recording period followed by weekly
CBT-I/QDT sessions for 8-weeks. CBT-I will be conducted according to a standard protocol. Weekly 1-hour
sessions (individual format) will be used to deliver the four components of CBT-I (Sleep Restriction, Stimulus
Control, Sleep Hygiene, and Cognitive therapy [sleep-related de-catastrophization]). Treatment will be followed
up with two evaluations at 3 and 6 months post-intervention. All subjects will complete the Insomnia Severity
Index, daily sleep diaries, and the alcohol-related measures for a 2-week baseline, for the intervention period,
and for two follow-up intervals after treatment completion at 3 and 6 months. The primary outcome measures
are insomnia severity (as assessed with the ISI) and percentage days abstinent (as assessed using the
Timeline Follow Back measure). In addition, health and mood will be tracked using the Short Form-12 (SF-12)
item scale, the BDI-II, PHQ9, STAI, and the GAD7. The combination of these measures serve to test the
hypotheses that standard CBT-I can be applied successfully in patients recovering from alcoholism and that
successful treatment of insomnia will be associated with better clinical outcomes in relation to alcoholism.
Finally, family history data will be assessed on an exploratory basis to assess differences in baseline insomnia
and objective sleep, as well as outcomes for the insomnia, alcoholism, treatment adherence, and/or treatment
outcome. Objective sleep will be preliminarily assessed with in-laboratory polysomnograms of seven subjects
with and without familial alcoholism (n=16). It is hypothesized that CBT-I in abstinent alcoholics will lead to 1)
significantly superior sleep-related outcomes as compared to QDT, 2) pre-to-post treatment effect sizes that
are comparable to the meta-analytic norms, 3) a larger percentage of days abstinent with at least a trend
toward fewer relapses, and 4) better overall health and mood. If these findings are achieved and replicated, it
will suggest that insomnia treatment should be a standard component in the management of alcoholism and
that CBT-I is an ideal management approach for this co-morbid insomnia.
酗酒和失眠在退伍军人中非常普遍。估计有6.4%的人酗酒
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Subhajit Chakravorty其他文献
Subhajit Chakravorty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Subhajit Chakravorty', 18)}}的其他基金
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
认知行为疗法 (CBT-I) 增强托吡酯促进酒精使用障碍 (AUD) 戒酒的作用。
- 批准号:
10013402 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
认知行为疗法 (CBT-I) 增强托吡酯促进酒精使用障碍 (AUD) 戒酒的作用。
- 批准号:
10578700 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
认知行为疗法 (CBT-I) 增强托吡酯促进酒精使用障碍 (AUD) 戒酒的作用。
- 批准号:
10394786 - 财政年份:2020
- 资助金额:
-- - 项目类别:
The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
CBT-I 对酗酒者的功效
- 批准号:
8811012 - 财政年份:2014
- 资助金额:
-- - 项目类别:
The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
CBT-I 对酗酒者的功效
- 批准号:
9240571 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
StuDy AimED at Increasing AlCohol AbsTinEnce (DEDICATE)
旨在提高酒精戒断率的研究(奉献)
- 批准号:
10577022 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A Controlled Study of Extended Cannabis Abstinence in Major Depression
重度抑郁症患者长期吸食大麻的对照研究
- 批准号:
478313 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Exercised-induced modulation of insular cortex microcircuitry during alcohol abstinence
戒酒期间运动诱导的岛叶皮质微电路调节
- 批准号:
10748763 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.
Prapela™ SVS:一种经济高效的随机振动触觉刺激装置,可改善患有新生儿戒断综合征的婴儿的临床过程。
- 批准号:
10837421 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Enforced alcohol abstinence: does it reduce reoffending?
强制戒酒:会减少再犯罪吗?
- 批准号:
ES/X003566/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fellowship
Neurobiological impact of acute digital media abstinence among drug using college students
吸毒大学生急性数字媒体戒断的神经生物学影响
- 批准号:
10677380 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Single-cell whole brain imaging of nicotine intoxication, dependence, and abstinence
尼古丁中毒、依赖和戒断的单细胞全脑成像
- 批准号:
10588509 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Understanding recovery from alcohol use disorder: Longitudinal observation of two voluntary temporary abstinence periods
了解酒精使用障碍的恢复:两个自愿临时戒酒期的纵向观察
- 批准号:
10740677 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Sleep Disturbances During Cocaine Abstinence, Dopamine Adaptations, and Motivation for Cocaine
可卡因戒断期间的睡眠障碍、多巴胺适应和可卡因动机
- 批准号:
10681668 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Transcriptional adaptations driving the intensification of alcohol-seeking in dependent rats undergoing prolonged abstinence
转录适应导致长期戒酒的依赖性大鼠对酒精的渴求加剧
- 批准号:
10540014 - 财政年份:2022
- 资助金额:
-- - 项目类别: